MedPath

UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN logo
🇺🇸United States
Ownership
Private
Established
1817-01-01
Employees
10K
Market Cap
-
Website
http://www.umich.edu

Clinical Trials

1.4k

Active:55
Completed:968

Trial Phases

6 Phases

Early Phase 1:17
Phase 1:64
Phase 2:82
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1185 trials with phase data)• Click on a phase to view related trials

Not Applicable
921 (77.7%)
Phase 2
82 (6.9%)
Phase 4
74 (6.2%)
Phase 1
64 (5.4%)
Phase 3
27 (2.3%)
Early Phase 1
17 (1.4%)

Usability of the MeTime MS App

Not Applicable
Active, not recruiting
Conditions
Multiple Sclerosis
Pain
Fatigue Symptom
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
University of Michigan
Target Recruit Count
10
Registration Number
NCT07123272
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Evaluating a Wearable Tracking System for Family Caregivers of Persons With Dementia With Wandering Concerns

Not Applicable
Not yet recruiting
Conditions
Dementia
Caregiver
Memory Loss
First Posted Date
2025-08-11
Last Posted Date
2025-08-11
Lead Sponsor
University of Michigan
Target Recruit Count
140
Registration Number
NCT07116122
Locations
🇺🇸

University of Michigan Transportation Research Institute, Ann Arbor, Michigan, United States

Population Based Strategies for Standardized Surgical Care

Not Applicable
Not yet recruiting
Conditions
Hernia, Abdominal
First Posted Date
2025-08-06
Last Posted Date
2025-08-06
Lead Sponsor
University of Michigan
Target Recruit Count
68
Registration Number
NCT07106541
Locations
🇺🇸

University of Michigan and other Michigan Surgical Quality Collaborative sites, Ann Arbor, Michigan, United States

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

Not Applicable
Recruiting
Conditions
Endometriosis
Pelvic Pain
Interventions
Drug: Relugolix CT
First Posted Date
2025-08-03
Last Posted Date
2025-08-14
Lead Sponsor
University of Michigan
Target Recruit Count
130
Registration Number
NCT07100782
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model

Not Applicable
Not yet recruiting
Conditions
Substance Use
Healthy
First Posted Date
2025-07-30
Last Posted Date
2025-07-30
Lead Sponsor
University of Michigan
Target Recruit Count
294
Registration Number
NCT07094061
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 283
  • Next

News

University of Michigan Develops At-Home Melanoma Detection Patch Using Microneedle Technology

Researchers at the University of Michigan have developed the ExoPatch, a silicone patch with star-shaped microneedles that can detect melanoma by capturing disease-specific exosomes from skin tissue.

Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments

Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.

Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

Mayo Clinic Researchers Discover Drug Treatment to Triple Donor Heart Preservation Time

Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.

DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH

• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.

Breakthrough T1D Invests $2.8 Million to Establish Joint Cardiorenal Center of Excellence for Type 1 Diabetes Research

Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.

Trump Administration Cancels $800 Million in LGBTQ Health Research Funding

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.

Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

Teen Substance Use Remains at Historic Lows in 2024, NIH Survey Reveals

Substance use among adolescents has maintained historically low levels for the fourth consecutive year following significant declines during the COVID-19 pandemic, according to the latest NIH-funded Monitoring the Future survey.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.